These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32900375)

  • 1. Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein.
    Landeck N; Strathearn KE; Ysselstein D; Buck K; Dutta S; Banerjee S; Lv Z; Hulleman JD; Hindupur J; Lin LK; Padalkar S; Stanciu LA; Lyubchenko YL; Kirik D; Rochet JC
    Mol Neurodegener; 2020 Sep; 15(1):49. PubMed ID: 32900375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity.
    Ysselstein D; Dehay B; Costantino IM; McCabe GP; Frosch MP; George JM; Bezard E; Rochet JC
    Acta Neuropathol Commun; 2017 Jan; 5(1):3. PubMed ID: 28069058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of impaired membrane interactions on α-synuclein aggregation and neurotoxicity.
    Ysselstein D; Joshi M; Mishra V; Griggs AM; Asiago JM; McCabe GP; Stanciu LA; Post CB; Rochet JC
    Neurobiol Dis; 2015 Jul; 79():150-63. PubMed ID: 25931201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxic effects of human and rodent variants of alpha-synuclein in vivo.
    Landeck N; Buck K; Kirik D
    Eur J Neurosci; 2017 Feb; 45(4):536-547. PubMed ID: 27893183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.
    Musacchio T; Rebenstorff M; Fluri F; Brotchie JM; Volkmann J; Koprich JB; Ip CW
    Ann Neurol; 2017 Jun; 81(6):825-836. PubMed ID: 28470693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential α-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity.
    Luna E; Decker SC; Riddle DM; Caputo A; Zhang B; Cole T; Caswell C; Xie SX; Lee VMY; Luk KC
    Acta Neuropathol; 2018 Jun; 135(6):855-875. PubMed ID: 29502200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of an aggregation-prone variant of alpha-synuclein used to model synucleinopathies.
    Masaracchia C; König A; Valiente-Gabioud AA; Peralta P; Favretto F; Strohäker T; Lázaro DF; Zweckstetter M; Fernandez CO; Outeiro TF
    Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140298. PubMed ID: 31676453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different Effects of α-Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements.
    Ruf VC; Nübling GS; Willikens S; Shi S; Schmidt F; Levin J; Bötzel K; Kamp F; Giese A
    ACS Chem Neurosci; 2019 Mar; 10(3):1649-1659. PubMed ID: 30605594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha synuclein dimers and oligomers are increased in overexpressing conditions in vitro and in vivo.
    Marmolino D; Foerch P; Atienzar FA; Staelens L; Michel A; Scheller D
    Mol Cell Neurosci; 2016 Mar; 71():92-101. PubMed ID: 26711807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-synuclein mutations impair axonal regeneration in models of Parkinson's disease.
    Tönges L; Szegö EM; Hause P; Saal KA; Tatenhorst L; Koch JC; D Hedouville Z; Dambeck V; Kügler S; Dohm CP; Bähr M; Lingor P
    Front Aging Neurosci; 2014; 6():239. PubMed ID: 25309425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
    Svarcbahs R; Julku UH; Myöhänen TT
    J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson's Disease.
    Lindberg I; Shu Z; Lam H; Helwig M; Yucer N; Laperle A; Svendsen CN; Di Monte DA; Maidment NT
    J Parkinsons Dis; 2022; 12(5):1463-1478. PubMed ID: 35527562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
    Lima VA; do Nascimento LA; Eliezer D; Follmer C
    ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-A decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models.
    Vinueza-Gavilanes R; Bravo-González JJ; Basurco L; Boncristiani C; Fernández-Irigoyen J; Santamaría E; Marcilla I; Pérez-Mediavilla A; Luquin MR; Vales A; González-Aseguinolaza G; Aymerich MS; Aragón T; Arrasate M
    Neurobiol Dis; 2023 Jul; 183():106166. PubMed ID: 37245833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
    Arawaka S; Fukushima S; Sato H; Sasaki A; Koga K; Koyama S; Kato T
    PLoS One; 2014; 9(2):e89076. PubMed ID: 24586512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
    Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
    PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy.
    Xilouri M; Vogiatzi T; Vekrellis K; Park D; Stefanis L
    PLoS One; 2009; 4(5):e5515. PubMed ID: 19436756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.